JP2016531131A - ヒト又は動物の微生物叢由来の有利な微生物のｉｎ ｖｉｔｒｏの濃縮によるプロバイオティクスの生成 - Google Patents

ヒト又は動物の微生物叢由来の有利な微生物のｉｎ ｖｉｔｒｏの濃縮によるプロバイオティクスの生成 Download PDF

Info

Publication number
JP2016531131A
JP2016531131A JP2016536059A JP2016536059A JP2016531131A JP 2016531131 A JP2016531131 A JP 2016531131A JP 2016536059 A JP2016536059 A JP 2016536059A JP 2016536059 A JP2016536059 A JP 2016536059A JP 2016531131 A JP2016531131 A JP 2016531131A
Authority
JP
Japan
Prior art keywords
sample
subject
probiotic composition
enterotoxiosis
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531131A5 (cg-RX-API-DMAC7.html
Inventor
コルト、レムコ
アンリ ヨハン シューレン、フランク
アンリ ヨハン シューレン、フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Publication of JP2016531131A publication Critical patent/JP2016531131A/ja
Publication of JP2016531131A5 publication Critical patent/JP2016531131A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016536059A 2013-08-22 2014-08-22 ヒト又は動物の微生物叢由来の有利な微生物のｉｎ ｖｉｔｒｏの濃縮によるプロバイオティクスの生成 Pending JP2016531131A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13181363.6 2013-08-22
EP13181363 2013-08-22
EP14163695.1 2014-04-07
EP14163695 2014-04-07
PCT/NL2014/050570 WO2015026235A2 (en) 2013-08-22 2014-08-22 Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota

Publications (2)

Publication Number Publication Date
JP2016531131A true JP2016531131A (ja) 2016-10-06
JP2016531131A5 JP2016531131A5 (cg-RX-API-DMAC7.html) 2017-12-07

Family

ID=51662286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536059A Pending JP2016531131A (ja) 2013-08-22 2014-08-22 ヒト又は動物の微生物叢由来の有利な微生物のｉｎ ｖｉｔｒｏの濃縮によるプロバイオティクスの生成

Country Status (4)

Country Link
US (1) US20160206668A1 (cg-RX-API-DMAC7.html)
EP (1) EP3035944B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016531131A (cg-RX-API-DMAC7.html)
WO (1) WO2015026235A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
WO2016183535A1 (en) * 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
IL281424B2 (en) 2015-06-09 2023-10-01 Rebiotix Inc Microbiota restoration treatment preparations and production methods
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10238597B2 (en) 2015-11-19 2019-03-26 Beauty Biolabs Llc Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
RU2662310C9 (ru) 2015-12-04 2018-09-21 Виктор Вениаминович Тец Средство (варианты) и способы восстановления микрофлоры
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
EP3538118B1 (en) * 2016-11-11 2021-03-03 Sjaellands Universitetshospital Dermatologisk Afdeling Saprophytic live bacteria for use in treatment of hidradenitis suppurativa
WO2020007931A1 (en) * 2018-07-04 2020-01-09 Chr. Hansen A/S Topical compositions comprising viable probiotic bacteria
US20200054693A1 (en) * 2018-08-17 2020-02-20 Scott Chamberlin Probiotic Solution
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
CA3202036A1 (en) * 2020-12-23 2022-06-30 Herve Affagard Method of expanding a complex community of microorganisms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118571A1 (en) * 1999-05-25 2003-06-26 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women during pregnancy and at other life stages, to reduce the risk of urogenital diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118571A1 (en) * 1999-05-25 2003-06-26 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women during pregnancy and at other life stages, to reduce the risk of urogenital diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNU REV NUTR, vol. 22, JPN6018021115, 2002, pages 107 - 138, ISSN: 0003961575 *
CLIN MICROBIOL INFECT, vol. 13, JPN6018021112, 2007, pages 657 - 664, ISSN: 0003961574 *

Also Published As

Publication number Publication date
WO2015026235A3 (en) 2015-08-27
US20160206668A1 (en) 2016-07-21
WO2015026235A2 (en) 2015-02-26
EP3035944B1 (en) 2019-10-02
EP3035944A2 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
EP3035944B1 (en) Probiotics for use in the treatment of bacterial vaginosis
US11116806B2 (en) Composite probiotic lactic acid bacteria powder and preparation method and use thereof
Sotoudegan et al. Reappraisal of probiotics’ safety in human
Wu et al. Effect of a multispecies probiotic mixture on the growth and incidence of diarrhea, immune function, and fecal microbiota of pre-weaning dairy calves
Davis Normal flora
JP4455333B2 (ja) プロバイオティック細菌：Ｌａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍ
WO2022218335A1 (zh) 罗伊氏乳杆菌及其应用、组合物、药物和食品
ES2436620T3 (es) Método para reducir la inflamación gastro-intestinal usando la bacteria Bifidobacterium animalis o un producto lácteo fermentado que comprende dicha bacteria
EA035698B1 (ru) Штамм bacteroides thetaiotaomicron ncimb 42341 для уменьшения воспаления ткани или органа
CN114376234A (zh) 活化的双歧杆菌及其应用方法
CN102272332A (zh) 乳酸菌及其在猪的直接饲喂微生物中的应用
CN101998834B (zh) 用于缓解胃肠道病症相关症状的益生菌
EP3651783A1 (en) New probiotic composition for prevention of bacterial vaginosis
CN109498660B (zh) 一种能够缓解特应性皮炎的植物乳杆菌ccfm8610的应用
Lee et al. Pioneer colonizers: Bacteria that alter the chicken intestinal morphology and development of the microbiota
WO2018112741A1 (zh) 一种嗜酸乳杆菌及其培养方法和应用
CN116077415B (zh) 一种用于调节皮肤微生态平衡的三元益生因子组合物
Toca et al. Gut ecosystem during infancy: The role of “biotics”
CN113041266B (zh) 一株改善银屑病样小鼠病理特征的干酪乳杆菌及其应用
Medjaoui et al. Isolation and Characterization of Lactic Acid Bacteria from Human Milk and Newborn Feces.
CN112546074A (zh) 一株能够抑制IL-23、Th17轴相关炎症因子释放的短双歧杆菌及其应用
Parija Clostridium
Neu The microbiome in prenatal and neonatal life
CN114540237B (zh) 一种用于早产儿小肠结肠炎中粪便菌群的培养基及应用
Zhou et al. Administration of probiotics reduces bacterial translocation after intestinal transplantation in rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190129